Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1971 1
1974 2
1975 2
1979 1
1980 1
1982 1
1984 2
1985 2
1986 5
1987 4
1988 6
1989 7
1990 13
1991 10
1992 11
1993 10
1994 18
1995 9
1996 29
1997 19
1998 15
1999 31
2000 28
2001 51
2002 69
2003 79
2004 80
2005 73
2006 103
2007 112
2008 123
2009 152
2010 154
2011 178
2012 192
2013 131
2014 123
2015 143
2016 142
2017 181
2018 152
2019 195
2020 187
2021 39
Text availability
Article attribute
Article type
Publication date

Search Results

2,600 results
Results by year
Filters applied: . Clear all
Page 1
The new biology of PTCL-NOS and AITL: current status and future clinical impact.
Timmins MA, Wagner SD, Ahearne MJ. Timmins MA, et al. Br J Haematol. 2020 Apr;189(1):54-66. doi: 10.1111/bjh.16428. Epub 2020 Feb 17. Br J Haematol. 2020. PMID: 32064593 Review.
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative disorders almost all of which are associated with poor clinical outcomes. ...While PTCL-NOS remains a diagnosis of exclusion, advances in genomics have identified sub …
Peripheral T-cell lymphomas (PTCL) comprise a heterogeneous group of aggressive lymphoproliferative disorders almost all of which are …
Microenvironmental immune cell signatures dictate clinical outcomes for PTCL-NOS.
Sugio T, Miyawaki K, Kato K, Sasaki K, Yamada K, Iqbal J, Miyamoto T, Ohshima K, Maeda T, Miyoshi H, Akashi K. Sugio T, et al. Blood Adv. 2018 Sep 11;2(17):2242-2252. doi: 10.1182/bloodadvances.2018018754. Blood Adv. 2018. PMID: 30194138 Free PMC article.
Peripheral T-cell lymphoma (PTCL), not otherwise specified (PTCL-NOS) is among the most common disease subtypes of PTCL, one that exhibits heterogeneous clinicopathological features. ...Our data also suggest functional interactions between cancerous T cells a …
Peripheral T-cell lymphoma (PTCL), not otherwise specified (PTCL-NOS) is among the most common disease subtypes of PTCL
New directions in treating peripheral T-cell lymphomas (PTCL): leveraging epigenetic modifiers alone and in combination.
Ma H, O'Connor OA, Marchi E. Ma H, et al. Expert Rev Hematol. 2019 Mar;12(3):137-146. doi: 10.1080/17474086.2019.1583102. Epub 2019 Feb 27. Expert Rev Hematol. 2019. PMID: 30782038 Review.
Finally, histone deacetylase inhibitors have unique activity in PTCL with four approved globally for patients with relapsed/refractory PTCL. ...Expert Opinion: In this review, we discuss the spectrum of novel therapies in PTCL, with a specific focus on epigen …
Finally, histone deacetylase inhibitors have unique activity in PTCL with four approved globally for patients with relapsed/refractor …
The aggressive peripheral T-cell lymphomas: 2017.
Armitage JO. Armitage JO. Am J Hematol. 2017 Jul;92(7):706-715. doi: 10.1002/ajh.24791. Am J Hematol. 2017. PMID: 28516671 Free article. Review.
DIAGNOSIS: The diagnosis of aggressive peripheral T-cell lymphoma (PTCL) is usually made using the World Health Organization classification. ...Natural killer/T-cell lymphoma localized to the nose and nasal sinuses seems to be best treated with radiotherapy-containing regi …
DIAGNOSIS: The diagnosis of aggressive peripheral T-cell lymphoma (PTCL) is usually made using the World Health Organization classifi …
Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
Zain JM. Zain JM. Am J Hematol. 2019 Aug;94(8):929-946. doi: 10.1002/ajh.25513. Epub 2019 Jun 11. Am J Hematol. 2019. PMID: 31119775 Free article. Review.
MOLECULAR PATHOGENESIS OF VARIOUS SUBTYPES OF PTCL: Gene expression profiling can help in diagnosis and prognostication of various subtypes including PTCL-nos and anaplastic large cell lymphoma. ...TARGETED THERAPIES: There are many targeted agents currently in vari …
MOLECULAR PATHOGENESIS OF VARIOUS SUBTYPES OF PTCL: Gene expression profiling can help in diagnosis and prognostication of various su …
Combined Oral 5-Azacytidine and Romidepsin are Highly Effective in Patients with PTCL: A Multicenter Phase 2 Study.
Falchi L, Ma H, Klein S, Lue JK, Montanari F, Marchi E, Deng C, Kim HA, Rada AM, Jacob AT, Kinahan C, Francescone M, Soderquist CR, Park DC, Bhagat G, Nandakumar R, Menezes DL, Scotto L, Sokol L, Shustov AR, O'Connor OA. Falchi L, et al. Blood. 2020 Nov 10:blood.2020009004. doi: 10.1182/blood.2020009004. Online ahead of print. Blood. 2020. PMID: 33171487
Peripheral T-cell lymphomas (PTCL) are uniquely vulnerable to epigenetic modifiers. We demonstrated in vitro synergism between histone deacetylase inhibitors and DNA methyltransferase inhibitors in preclinical models of T-cell lymphoma. In a phase 1 trial we found oral 5-a …
Peripheral T-cell lymphomas (PTCL) are uniquely vulnerable to epigenetic modifiers. We demonstrated in vitro synergism between histon …
Clinicopathological analysis in PTCL-NOS with CADM1 expression.
Kato T, Miyoshi H, Kobayashi S, Yoshida N, Imaizumi Y, Seto M, Uchimaru K, Miyazaki Y, Ohshima K. Kato T, et al. Virchows Arch. 2017 Nov;471(5):659-666. doi: 10.1007/s00428-017-2233-9. Epub 2017 Sep 22. Virchows Arch. 2017. PMID: 28940014
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), is a heterogeneous disease with respect to clinicopathological features. ...Multivariate analysis confirmed that CADM1 expression was an independent prognostic factor in PTCL-NOS. These findings suggest …
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS), is a heterogeneous disease with respect to clinicopathological featur …
Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.
Heavican TB, Bouska A, Yu J, Lone W, Amador C, Gong Q, Zhang W, Li Y, Dave BJ, Nairismägi ML, Greiner TC, Vose J, Weisenburger DD, Lachel C, Wang C, Fu K, Stevens JM, Lim ST, Ong CK, Gascoyne RD, Missiaglia E, Lemonnier F, Haioun C, Hartmann S, Pedersen MB, Laginestra MA, Wilcox RA, Teh BT, Yoshida N, Ohshima K, Seto M, Rosenwald A, Ott G, Campo E, Rimsza LM, Jaffe ES, Braziel RM, d'Amore F, Inghirami G, Bertoni F, de Leval L, Gaulard P, Staudt LM, McKeithan TW, Pileri S, Chan WC, Iqbal J. Heavican TB, et al. Blood. 2019 Apr 11;133(15):1664-1676. doi: 10.1182/blood-2018-09-872549. Epub 2019 Feb 19. Blood. 2019. PMID: 30782609 Free PMC article.
Angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS) are the 2 most frequent categories, accounting for >50% of PTCLs. ...Co-occurring gains/amplifications of STAT3 and MYC occurred in PTCL-GATA3. Several CNAs, in particula …
Angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS) are the 2 most frequent categories, acco …
Reproducing the molecular subclassification of peripheral T-cell lymphoma-NOS by immunohistochemistry.
Amador C, Greiner TC, Heavican TB, Smith LM, Galvis KT, Lone W, Bouska A, D'Amore F, Pedersen MB, Pileri S, Agostinelli C, Feldman AL, Rosenwald A, Ott G, Mottok A, Savage KJ, de Leval L, Gaulard P, Lim ST, Ong CK, Ondrejka SL, Song J, Campo E, Jaffe ES, Staudt LM, Rimsza LM, Vose J, Weisenburger DD, Chan WC, Iqbal J. Amador C, et al. Blood. 2019 Dec 12;134(24):2159-2170. doi: 10.1182/blood.2019000779. Blood. 2019. PMID: 31562134 Free PMC article.
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of mature T-cell malignancies; approximately one-third of cases are designated as PTCL-not otherwise specified (PTCL-NOS). Using gene-expression profiling (GEP), we have previously defined 2 major mol …
Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of mature T-cell malignancies; approximately one-third of cases are design …
Development of new agents for peripheral T-cell lymphoma.
Ito Y, Makita S, Tobinai K. Ito Y, et al. Expert Opin Biol Ther. 2019 Mar;19(3):197-209. doi: 10.1080/14712598.2019.1572746. Epub 2019 Jan 29. Expert Opin Biol Ther. 2019. PMID: 30658046 Review.
To improve the outcome of patients with PTCL, the clinical development of several novel agents is currently under investigation. ...In this review, we have summarized the available data regarding these approved agents and new agents currently under development for PTCL
To improve the outcome of patients with PTCL, the clinical development of several novel agents is currently under investigation. ...I …
2,600 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page